Arbutus Biopharma Corporation (ABUS) is priced at $3.93 after the most recent trading session. At the very opening of the session, the stock price was $3.93 and reached a high price of $4.495, prior to closing the session it reached the value of $4.30. The stock touched a low price of $3.81.
Recently in News on July 29, 2020, Arbutus to Report Second Quarter 2020 Financial Results. Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its second quarter financial results, conference call and webcast for Friday, August 7, 2020. The schedule for the press release and conference call/webcast are as follows:. You can read further details here
Arbutus Biopharma Corporation had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $9.02 on 07/24/20, with the lowest value was $0.88 for the same time period, recorded on 04/03/20.
Arbutus Biopharma Corporation (ABUS) full year performance was 141.57%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Arbutus Biopharma Corporation shares are logging -56.43% during the 52-week period from high price, and 378.45% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.82 and $9.02.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2753932 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Arbutus Biopharma Corporation (ABUS) recorded performance in the market was 54.68%, having the revenues showcasing 270.69% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 370.70M, as it employees total of 80 workers.
The Analysts eye on Arbutus Biopharma Corporation (ABUS)
During the last month, 0 analysts gave the Arbutus Biopharma Corporation a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.92, with a change in the price was noted +1.19. In a similar fashion, Arbutus Biopharma Corporation posted a movement of +42.81% for the period of last 100 days, recording 5,318,349 in trading volumes.
Technical rundown of Arbutus Biopharma Corporation (ABUS)
Raw Stochastic average of Arbutus Biopharma Corporation in the period of last 50 days is set at 31.94%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 30.92%. In the last 20 days, the company’s Stochastic %K was 32.74% and its Stochastic %D was recorded 33.14%.
Considering, the past performance of Arbutus Biopharma Corporation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 54.68%. Additionally, trading for the stock in the period of the last six months notably improved by 54.12%, alongside a boost of 141.57% for the period of the last 12 months. The shares increased approximately by -30.65% in the 7-day charts and went down by 136.26% in the period of the last 30 days. Common stock shares were driven by 270.69% during last recorded quarter.